Non-alcoholic fatty liver disease following liver transplantation: A clinical review

Clinical Transplantation

Volumn 29, Issue 9, 2015, Pages 728-737

  Merola, Jonathan ^a   Liapakis, Annmarie ^a   Mulligan, David C ^a   Yoo, Peter S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fatty liver disease; Non alcoholic steatohepatitis; Transplantation

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIRAGLUTIDE; METFORMIN; OBETICHOLIC ACID; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;

BARIATRIC SURGERY; CARDIOVASCULAR RISK; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIFESTYLE MODIFICATION; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; ORGAN DONOR; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CARDIOVASCULAR DISEASES; METABOLIC SYNDROME X; MULTIMODALITY CANCER THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; POSTOPERATIVE COMPLICATIONS; RISK FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; HUMANS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84940959302     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12585     Document Type: Review

References (89)

1. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011: 141: 1249.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980: 55: 434.
3. Wong RJ, Aguilar M, Cheung R et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015: 148: 547.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002: 346: 1221.
5. Rafiq N, Bai C, Fang Y et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroentrol Hepatol 2009: 7: 234.
6. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002: 123: 134.
7. Bianchi G, Marchesini R, Marzochi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008: 14: 1648.
8. Fracanzani AL, Burdick L, Raselli S et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008: 121: 72.
9. Charlton M, Kasparova P, Weston S et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001: 7: 608.
10. Contos MJ, Cales W, Stering RK et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001: 7: 363.
11. Malik SM, deVera MR, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009: 9: 782.
12. Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009: 15: 1814.
13. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008: 21: 459.
14. Tiniakos DG. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems. Eur J Gastroenterol Hepatol 2010: 22: 643.
15. Straub BK, Schirmacher P. Pathology and biopsy assessment of non-alcoholic fatty liver disease. Dig Dis 2010: 28: 197.
16. Patil DT, Yerian LM. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. Liver Transpl 2012: 18: 1147.
17. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012: 55: 2005.
18. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004: 40: 578.
19. Matsui O, Kadoya M, Takahashi S et al. Focal sparing of segment IV in fatty livers shown by sonography and CT: correlation with aberrant gastric venous drainage. Am J Roentgenol 1995: 164: 1137.
20. Schaffner F, Poper H. Capillarization of hepatic sinusoids. Gastroenterology 1963: 44: 239.
21. Nosadini R, Avogaro A, Mollo F et al. Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow. J Clin Endocrinol Metab 1984: 58: 1125.
22. Soderberg C, Stal P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010: 51: 595.
23. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005: 41: 1313.
24. Siddiqui MS, Sterling RK. Posttransplant metabolic syndrome. Int J Hepatol 2012: 2012: 891516.
25. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011: 17: 15.
26. El Atrache MM, Abouljoud MS, Divine G et al. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. Clin Transplant 2012: 26: E505.
27. Dureja P, Mellinger J, Agni R et al. NAFLD recurrence in liver transplant recipients. Transplantation 2011: 91: 684.
28. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002: 96: 23.
29. Ozbay LA, Smidt K, Mortensen DM, Carstens J, Jorgensen KA, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol 2011: 162: 136.
30. Houlihan DD, Armstrong MJ, Davidov Y et al. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens? Liver Transpl 2011: 17: 1292.
31. Dumortier J, Giostra E, Belbouab S et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil." Am J Gastroenterol 2010: 105: 613.
32. Kim H, Lee K, Lee KW et al. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transplant 2014: 28: 521.
33. Finkenstedt A, Auer C, Glodny B et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplant is a risk factor for graft steatosis. Clin Gastroenterol Hepatol 2013: 11: 1667.
34. Dunn W, O'Neil M, Zhoa J et al. Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C. Hepatology 2014: 59: 453.
35. Newsome PN, Allison ME, Andrews PA et al. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 2012: 61: 484.
36. Agopian VG, Kaldas FM, Hong JC et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 2012: 256: 624.
37. Oetting WS, Guan W, Schladt DP et al. Donor polymorphisms of toll-like receptor 4 associated with graft failure in liver transplant recipients. Liver Transpl 2012: 18: 1399.
38. Kennedy C, Redden D, Gray S et al. Equivalent survival following liver transplantation in patients with nonalcoholic steatohepatitis compared with patients with other liver diseases. HPB 2012: 14: 625.
39. Heuer M, Kaiser G, Kahraman A et al. Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion 2012: 86: 107.
40. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014: 12: 394.
41. VanWagner LB, Lapin B, Skaro AI, Lloyd-Jones DM, Rinella ME. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int 2015 doi: 10.1111/liv.12872 [Epub ahead of print].
42. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002: 73: 901.
43. Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012: 18: 29.
44. Hernandez-Alejandro R, Croome KP, Drage M et al. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. World J Gastroenterol 2012: 18: 4145.
45. O'Leary JP, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and crytogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol 2011: 9: 700.
46. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010: 16: 431.
47. Charlton M. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant 2013: 18: 251.
48. Promrat K, Kleiner DE, Neimeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010: 51: 121.
49. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015: 149: 367.
50. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009: 50: 68.
51. Fields M, Lewis CG, Lure MD. Responses of insulin to oral glucose and fructose loads in marginally copper-deficient rats fed starch or fructose. Nutrition 1996: 12: 524.
52. Capanni M, Calella F, Biagini MR et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006: 23: 1143.
53. Sanyal AJ, Chalsani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010: 362: 1675.
54. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Syst Rev 2007: CD004996.
55. Cuschieri JR, John BK, Miick R, Ortiz JA, Hashemi N. Successful treatment of rapid onset, symtompatic, de novo non-alcoholic steatohepatitis following liver transplantation: a case report. J Clin Exp Heptol 2013: 3: 70.
56. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St. Francis Heart study randomized clinical trial. Am J Gastroenterol 2011: 106: 71.
57. Cho Y, Lee MJ, Choe EY et al. Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels. Liver Transpl 2014: 20: 557.
58. Ackerman Z, Oron-Herman M, Grozovski M et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 2005: 45: 1012.
59. Toblli JE, Ferder L, Stella I, Angerosa M, Inserra F. Enalapril prevents fatty liver in nephrotic rats. J Nephrol 2002: 15: 358.
60. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005: 115: 209.
61. Seo S, Maganti K, Khehra M et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007: 13: 844.
62. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007: 16: 39.
63. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild- to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009: 15: 942.
64. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994: 30: 603.
65. Hepgul G, Tanrikulu S, Unalp HR et al. Preventative effect of pentoxifylline on acute radiation damage via antioxidant and anti-inflammatory pathways. Dig Dis Sci 2010: 55: 617.
66. Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2014: 20: 569.
67. Uygun A, Kadayifci A, Isik AT et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004: 19: 537.
68. Doycheva I, Loomba R. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NALFD). Adv Ther 2014: 31: 30.
69. Nobili V, Manco M, Ciampalini P et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008: 30: 1168.
70. Angelico F, Burrattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007: 1: CD005166.
71. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot study. Therap Adv Gastroenterol 2009: 2: 157.
72. Idilman R, Mizrak D, Corapcioglu D et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008: 28: 200.
73. Omer Z, Cetinkalp S, Akyildiz M et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010: 22: 18.
74. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain 19 February 2003. Transplantation 2003: 75: SS3.
75. Kobayashi T, Sato Y, Yamamoto S et al. Successful management of a type 2 diabetic donor in living-donor liver transplantation: a case report. Transplant Proc 2008: 40: 2842.
76. Jankowska I, Socha P, Pawlowska J et al. Recurrence of non-alcoholic steatohepatitis after liver transplantation in a 13-year-old boy. Pediatr Transplant 2007: 11: 796.
77. Belfort R, Harrison SA, Brown KA et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006: 355: 2297.
78. Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis- a systematic review and meta analysis. J Hepatol 2011: 55: 1383.
79. Turner RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2014: 78: 258.
80. Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicenter, randomized, placebo-controlled trial. Lancet 2015: 385: 956.
81. Wilkison W, Cheatham B, Walker S. Remogliflozin etabonate reduces insulin resistance and liver function enzymes: role for treatment of NASH. 24 Apr 2014. Poster presented at International Liver Congress, Vienna, Austria.
82. Armstrong MJ, Barton D, Gaunt P et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre double-blinded, randomized, controlled trial. BMJ Open 2013: 3: e003995.
83. Colter SJ, Vitello JM, Guzman G, Testa G, Benedetti E, Layden TJ. Hepatic decompensation after gastric bypass surgery for severe obesity. Dig Dis Sci 2004: 49: 1563.
84. Butte J, Devaud N, Jarufe NP et al. Sleeve gastrectomy for treatment for severe obesity after orthotopic liver transplantation. Obes Surg 2007: 17: 1517.
85. Lin MY, Tavakol MM, Sarin A et al. Safety and feasibility of sleeve gastrectomy in morbidly obese patients following liver transplantation. Surg Endosc 2013: 27: 81.
86. Duchini A, Brunson ME. Roux-en-Y gastric bypass for recurrent nonalcoholic stetohepatitis in liver transplant recipients with morbid obesity. Transplantation 2001: 72: 156.
87. Takata MC, Campos GM, Clovica R et al. Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation. Surg Obes Relat Dis 2008: 4: 159.
88. Marszalek R, Ziemianski P, Lagiewska B et al. The first Polish liver transplantation after Roux-en-Y gastric bypass surgery for morbid obesity: a case report and literature review. Ann Transplant 2015: 20: 112.
89. Heimbach JK, Watt KD, Poterucha JJ et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant 2013: 13: 363.